Insights on the 4th Young Investigators Forum in Lung Cancer - priME Oncology
Webcast
Webcast

Insights on the 4th Young Investigators Forum in Lung Cancer

Developing the Next Generation of Leaders

Not a member of My prIME? Join now for instant access.

Learn from established senior investigators as they discuss how to succeed in transitional and clinical research, with relevant and stimulating presentations in lung cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

4.5 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Jun 27, 2019

Expiration Date

Jun 27, 2020

Plenary Session I

How to write an investigator-initiated trial
Nasser Hanna, MD

Considerations for participation in industry trials
Shirish Gadgeel, MD

Cooperative groups
Heather Wakelee, MD

Plenary Session II

Leadership skills
Gary Teal

Presentation skills
Judy Fortin

Plenary Session III

Case #1–Small cell lung cancer
Case presenter: Erik Knelson, MD, PhD
Faculty discussant: Leora Horn, MD, MSc

Case #2–Stage III NSCLC
Case presenter: Jennifer Carlisle, MD
Faculty discussant: Nasser Hanna, MD

Case #3–Targeted therapy: First-line and beyond
Case presenter:  Nicolas Villanueva, MD
Faculty discussant: Lecia Sequist, MD, MPH

  • Jennifer Carlisle, MDEmory University
    Atlanta, Georgia, United States
  • Judy FortinWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Shirish Gadgeel, MDUniversity of Michigan
    Ann Arbor, Michigan, United States
  • Nasser Hanna, MDMelvin and Bren Simon Cancer Center
    Indiana University
    Indianapolis, Indiana, United States
  • Leora Horn, MD, MScVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States
  • Erik Henry Knelson, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Lecia V. Sequist, MD, MPHMassachusetts General Hospital Cancer Center
    Harvard Medical School
    Boston, Massachusetts, United States
  • Gary L. Teal, MBAWoodruff Health Sciences Center
    Emory University
    Atlanta, Georgia, United States
  • Nicolas Villanueva, MDUniversity of California
    San Diego, California, United States
  • Heather Wakelee, MDStanford University
    Stanford, California, United States

The target audience for this activity includes medical oncologist junior faculty (MD or DO who has completed a fellowship within the past 5 years) and fellows (actively enrolled in a fellowship program) who are pursuing careers in lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess the rationales, design, and endpoints in clinical trials investigating treatment options for lung cancer
  • Select treatment for lung cancer based upon disease and patient characteristics
  • Evaluate recent data from national society meetings that have the potential to impact practice including: immunotherapy, targeted therapies, sequencing, and combination therapy

This educational activity is supported by a grant from AstraZeneca.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.   Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 4.5 hour(s)

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Carlisle reported that she has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Judy Fortin has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Gadgeel has disclosed that he has received consulting fees from AstraZeneca, Bristol Myers-Squibb, Genentech, Roche, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hanna has disclosed contracted research from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Horn has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, and Incyte. She has received fees for non-CME services received directly from a commercial interest from Merck, Tesaro, and Xcovery. She also disclosed contracted research from Boehringer Ingelheim, Bristol-Myers Squibb, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Knelson has reported that he holds a patent for the preliminary method to promote delivery of STING agonists, but no financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sequist has disclosed that she has received consulting fees from AstraZeneca, Genentech, Janssen, and Merrimack. She has also disclosed that she has received an honorarium from AstraZeneca. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Gary Teal disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Villanueva has reported that he has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wakelee has disclosed that she has participated on an advisory board for AstraZeneca. She also disclosed grants for clinical research to her institution from ACEA Biosciences; AstraZeneca/Medimmune; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; Genentech/Roche; Gilead; Lilly; Merck and Co., Inc; Novartis; Pfizer; Pharmacyclics; and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Zach Hartman, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Clovis Oncology; F. Hoffmann-La Roche Ltd; ImmunoGen; Merck KGaA, Darmstadt, Germany; Pfizer; Novartis Oncology; Puma Biotechnology; and Tesaro

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.